FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387163071> ?p ?o ?g. }

• W4387163071 abstract "PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines ." @default.
• W4387163071 created "2023-09-30" @default.
• W4387163071 creator A5004799675 @default.
• W4387163071 creator A5005273991 @default.
• W4387163071 creator A5016574266 @default.
• W4387163071 creator A5016683007 @default.
• W4387163071 creator A5027938558 @default.
• W4387163071 creator A5031343159 @default.
• W4387163071 creator A5033960518 @default.
• W4387163071 creator A5035911030 @default.
• W4387163071 creator A5045353148 @default.
• W4387163071 creator A5049947325 @default.
• W4387163071 creator A5051388864 @default.
• W4387163071 creator A5052483047 @default.
• W4387163071 creator A5054315303 @default.
• W4387163071 creator A5054848065 @default.
• W4387163071 creator A5059768717 @default.
• W4387163071 creator A5060564611 @default.
• W4387163071 creator A5068503288 @default.
• W4387163071 creator A5072727753 @default.
• W4387163071 creator A5073652146 @default.
• W4387163071 creator A5077371911 @default.
• W4387163071 creator A5078324746 @default.
• W4387163071 creator A5079284639 @default.
• W4387163071 creator A5081606866 @default.
• W4387163071 creator A5087426330 @default.
• W4387163071 creator A5090608376 @default.
• W4387163071 creator A5092965372 @default.
• W4387163071 date "2023-09-29" @default.
• W4387163071 modified "2023-10-10" @default.
• W4387163071 title "Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline" @default.
• W4387163071 cites W1575433014 @default.
• W4387163071 cites W1806130404 @default.
• W4387163071 cites W2005741240 @default.
• W4387163071 cites W2014841614 @default.
• W4387163071 cites W2033786785 @default.
• W4387163071 cites W2083853142 @default.
• W4387163071 cites W2086374856 @default.
• W4387163071 cites W2115686439 @default.
• W4387163071 cites W2123331484 @default.
• W4387163071 cites W2124215468 @default.
• W4387163071 cites W2128596214 @default.
• W4387163071 cites W2135049144 @default.
• W4387163071 cites W2135400982 @default.
• W4387163071 cites W2137142564 @default.
• W4387163071 cites W2148933046 @default.
• W4387163071 cites W2158474413 @default.
• W4387163071 cites W2170915815 @default.
• W4387163071 cites W2201429547 @default.
• W4387163071 cites W2209368665 @default.
• W4387163071 cites W2229261843 @default.
• W4387163071 cites W2232569012 @default.
• W4387163071 cites W2297358564 @default.
• W4387163071 cites W2340185896 @default.
• W4387163071 cites W2346298590 @default.
• W4387163071 cites W2418960531 @default.
• W4387163071 cites W2519244199 @default.
• W4387163071 cites W2549006299 @default.
• W4387163071 cites W2549249508 @default.
• W4387163071 cites W2567362164 @default.
• W4387163071 cites W2573369749 @default.
• W4387163071 cites W2597360314 @default.
• W4387163071 cites W2604934199 @default.
• W4387163071 cites W2608160487 @default.
• W4387163071 cites W2625330427 @default.
• W4387163071 cites W2626441915 @default.
• W4387163071 cites W2646835579 @default.
• W4387163071 cites W2756245626 @default.
• W4387163071 cites W2756974671 @default.
• W4387163071 cites W2797093247 @default.
• W4387163071 cites W2888018398 @default.
• W4387163071 cites W2891044561 @default.
• W4387163071 cites W2897037536 @default.
• W4387163071 cites W2908066730 @default.
• W4387163071 cites W2911179395 @default.
• W4387163071 cites W2914495769 @default.
• W4387163071 cites W2914914251 @default.
• W4387163071 cites W2917124294 @default.
• W4387163071 cites W2952495208 @default.
• W4387163071 cites W2969542839 @default.
• W4387163071 cites W2995074379 @default.
• W4387163071 cites W3015314028 @default.
• W4387163071 cites W3017335713 @default.
• W4387163071 cites W3027911564 @default.
• W4387163071 cites W3048604500 @default.
• W4387163071 cites W3093659068 @default.
• W4387163071 cites W3096610241 @default.
• W4387163071 cites W3135402644 @default.
• W4387163071 cites W3212581461 @default.
• W4387163071 cites W4210985377 @default.
• W4387163071 cites W4213052925 @default.
• W4387163071 cites W4220652378 @default.
• W4387163071 cites W4220681742 @default.
• W4387163071 cites W4220855109 @default.
• W4387163071 cites W4225880044 @default.
• W4387163071 cites W4280605775 @default.
• W4387163071 cites W4295817609 @default.
• W4387163071 cites W4296846471 @default.
• W4387163071 cites W4306822619 @default.
• W4387163071 cites W4310040010 @default.

• next